Botox, which AbbVie gained through its $64 billion acquisition of Allergan in May, suffered an initial hit during the peak of the health crisis, but demand has since improved. AbbVie's portfolio of aesthetic medicines such as Botox was showing a "V-shaped recovery," Chief Executive Officer Richard Gonzalez said in a statement. Humira brought in sales of $5.14 billion and AbbVie's newer psoriasis medicine Skyrizi generated $435 million in the quarter ended Sept. 30.
AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2020.
NEW YORK, NY / ACCESSWIRE / October 30, 2020 / AbbVie, Inc.